Still, whether oncologists and patients are making optimal choices remains to be seen.
Oncotype DX, a 21-gene reverse transcriptase polymerase chain reaction assay, provides a recurrence score (RS) in patients with node-negative, estrogen-receptor (ER)–positive breast cancer. This test has been validated with archived tumor samples from completed clinical trials. The Web-based tool Adjuvant! Online uses traditional tumor characteristics (e.g., size, histologic grade, nodal metastasis) to estimate recurrence risk and benefit of adjuvant chemotherapy. In a prospective study of 979 chemotherapy-eligible patients at treatment centers throughout Ontario in 2012–2013 who had ER-positive, HER2-negative, node-negative or micrometastatic breast cancer, investigators assessed oncologists' and patients' preliminary preferences regarding…
Reviewing Author
DisclosuresLeadership Positions in Professional SocietiesAssociation of Women Surgeons (Member, Publications Committee)
DisclosuresLeadership Positions in Professional SocietiesAssociation of Women Surgeons (Member, Publications Committee)